Modality
Cell Therapy
MOA
SGLT2i
Target
BCL-2
Pathway
Hedgehog
GIST
Development Pipeline
Preclinical
~Feb 2019
→ ~May 2020
Phase 1
~Aug 2020
→ ~Nov 2021
Phase 2
Feb 2022
→ Jan 2027
Phase 2Current
NCT08008216
1,699 pts·GIST
2022-02→2027-01·Terminated
1,699 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-01-1810mo awayPh3 Readout· GIST
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027
P2/3
Termina…
Catalysts
Ph3 Readout
2027-01-18 · 10mo away
GIST
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08008216 | Phase 2/3 | GIST | Terminated | 1699 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| Motazanubrutinib | Biogen | Preclinical | CD38 | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 | |
| ARG-4339 | Argenx | Phase 2 | BCL-2 | |
| GMA-729 | Genmab | Phase 2 | BCL-2 |